Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Humacyte Inc shares valued at $9,999 were purchased by Scheessele William John on Apr 14 ’25. At $1.54 per share, Scheessele William John acquired 6,493 shares. The insider’s holdings grew to 22,018 shares worth approximately $53503.740000000005 following the completion of this transaction.
Also, Sander Dale A. purchased 20,000 shares, netting a total of over 30,600 in proceeds. Following the buying of shares at $1.53 each, the insider now holds 40,600 shares.
Before that, Parikh Shamik J had added 7,500 shares to its account. In a trade valued at $11,625, the Chief Medical Officer bought Humacyte Inc shares for $1.55 each. Upon closing the transaction, the insider’s holdings increased to 7,500 shares, worth approximately $18225.0.
Analysts at H.C. Wainwright resumed the stock at ‘”a Buy”‘ outlook in a report released in mid December. As of December 11, 2023, H.C. Wainwright has initiated its “Buy” rating for HUMA. Earlier on August 14, 2023, Piper Sandler upgraded its rating. Their new recommendation was “a Neutral” for HUMA stock which previously was a “an Underweight”.
Analyzing HUMA Stock Performance
On last trading session,, Humacyte Inc [NASDAQ: HUMA] rose 2.53% to $2.43. The stock’s lowest price that day was $2.32, but it reached a high of $2.455 in the same session. During the last five days, there has been a drop of approximately -10.99%. Over the course of the year, Humacyte Inc shares have dropped approximately -69.40%.
Support And Resistance Levels for Humacyte Inc (HUMA)
RSI (Relative Strength Index) is 51.12 on the 14-day chart, showing neutral technical sentiment.
Is Humacyte Inc subject to short interest?
Stocks of Humacyte Inc saw a sharp rise in short interest on 2025-07-15 jumping by 4.29 million shares to 32.72 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 28.43 million shares. A jump of 13.13% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 9.62 of the overall float, the days-to-cover ratio (short ratio) jumped to 9.62.
Which companies own the most shares of Humacyte Inc (HUMA)?
In terms of Humacyte Inc share price expectations, FactSet research, analysts set an average price target of 6 in the next 12 months, up nearly 153.16% from the previous closing price of $2.37. Analysts anticipate Humacyte Inc stock to reach 10 by 2025, with the lowest price target being 5. In spite of this, 2 analysts ranked Humacyte Inc stock as Buy at the end of 2025. On June 22, 2023, Cantor Fitzgerald assigned a price target of “an Overweight” to the stock and initiated coverage with a $6.
